Novavax Inc (NVAX)

[LongRun8]

No new insight. Everything is pretty much as NVAX has been describing on their calls and PRs. They are hitting almost of their of deadlines for trial initiations and completions (except for the pedi RSV vaccine trial, which a while ago they said was going to have delayed enrollment). Ph3 and Ph2 trials are starting, further investigating RSV vaccines in different patient populations. Also awaiting FDA guidance on Ph3 trial design for maternal RSV. So there will be some data to look forward to in Q3/Q4 2016 for which we should have some (hopefully) impressive readouts. Of course, we could always hear some news about NVAX's Ebola vaccine as other companies' Ebola vax candidates may continue to fail. I, however, am not holding my breath on any gov't funding for now given that they already sponsored a couple other companies and the Ebola threat seems to have gone away. While RSV and flu vaccines are NVAX's major pipeline components, they continue to impress with their ability to make an effective vaccine within 90 days after the viral genome is mapped. That's faster than anybody else. The only reason they didn't get funding for their Ebola vaccine was because other companies already had candidates in their pipeline. NVAX was "late" to the game, but one might argue that they were able to very quickly develop a candidate and maybe even the most effective one (with the added characteristic of not needing to be frozen). I was anticipating Q3 2015 for quite some time, but I think Q3/Q4 2016 will be just as exciting.